Investigation Report on China's Sertraline Market, 2010-2019

Aug 17, 2015, 08:10 ET from Research and Markets

DUBLIN, Aug. 17, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/cpltvp/investigation) has announced the addition of the "Investigation Report on China's Sertraline Market, 2010-2019" report to their offering.

According to WHO, depression, an affective mental disorder, is quite common with an incidence of 3-5%. Currently, the number of depression patients has exceeded 90 million in China and still keeps increasing. It is expected that by 2020, depression will become the second biggest threat to human health.

Developed by Pfizer, Inc. in the early 1990s, sertraline (sertraline dydrochloride) has entered many countries like the US, European countries and Japan to treat dysthymi and has brought in an annual sales value of over 1 billion all over the world. As the newest product of selective serotonin reuptake inhibitor (SSRI), sertraline can help improve organism ability, reduce symptoms of depression like distress and alleviate persistent fatigue and anxiety. As one of the three SSRI drugs with certain efficacy (the other two being fluoxetine and paroxetine), sertraline has been widely used for the treatment of depressive disorder and obsessive-compulsive disorder.

According to the market survey, sertraline keeps growing with annual sales value rising from CNY 20 million in 2005 to CNY 148 million in 2014 and CAGR during this period reaching 23.50% after it entered China in 1996. Pfizer, Inc., Zhejiang Jingxin Pharmaceutical Co., Ltd, Tianjin Huajin Pharmaceutical Factory, Guangdong P.D. Pharmaceutical Co., Ltd and Chengdu Leer Pharmaceutical Co., Ltd occupy the majority of the Chinese market, among of which Pfizer, Inc. had the largest market share of about 83% for sales value in 2014.

With the increased mental pressure brought about by economic development and lifestyle change, the number of depression patients keeps growing too. Therefore, the market size of sertraline is expected to expand in the next few years in China.

Key Topics Covered:

1 Related Concepts of Sertraline

2 Market Profile of Sertraline in China

3 Survey on Sales Status of Sertraline in China, 2010-2014

4 Survey on Market Share of Major Manufacturers of Sertraline in China, 2010-2014

5 Survey on Dosage Forms of Sertraline in China, 2010-2014

6 Reference Price of Sertraline in Chinese Hospitals in 2014

7 Major Manufacturers of Sertraline in Chinese Market, 2010-2014

8 Market Ooutlook of Sertraline in China, 2015-2019

Companies Mentioned

- Zhejiang Jingxin Pharmaceutical Co., Ltd - Tianjin Huajin Pharmaceutical Factory - Guangdong P.D. Pharmaceutical Co., Ltd - Zhejiang Huahai Pharmaceutical Co., Ltd - Pfizer, Inc.

For more information visit http://www.researchandmarkets.com/research/cpltvp/investigation

Media Contact:

Laura Wood, +353-1-481-1716, press@researchandmarkets.net

 

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com